Brief: Oramed Reaches 75% Enrollment In Phase 3 Oral Insulin Study
23/11/2021 13:48
Nov 23 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED REACHES 75% ENROLLMENT IN PHASE 3 ORAL INSULIN
STUDY
* ORAMED - NEARING END OF ENROLLMENT IN PHASE 3 ORAL INSULIN
STUDY
CONDUCTED UNDER FDA PROTOCOLS, ANTICIPATE ANNOUNCING TOPLINE
RESULTS IN 2022
Source text for Eikon: ID:nPn7xCYdVa
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results